Location: United Kingdom
The low-cost test will only require a blood sample to screen for early-stage cancers.
Global cancer rates are on the rise, with an estimated 43% increase by 2035. A better likelihood for a positive outcome is when the cancer is detected in the early stages. However, many cancers are asymptomatic until they progress. Regular screening is a good option, but testing is only currently suitable for some cancers such as cervical, bowel and breast cancer.
ClinSpec Dx, founded in Scotland in 2016, is working towards a blood test that can detect early-stage cancers. Their fast screening solution only requires a small blood sample from the patient and is termed a liquid biopsy. A drop of blood is placed on the optical sample slide, which then gets analysed using infrared light. It detects data from a variety of components within minutes, the artificial intelligence algorithm can then detect cancer signals.
The availability of an affordable cancer screening tool means cancer diagnoses can occur potentially prior to the patient starting to present with symptoms. Early detection will allow treatment to begin earlier and give patients the best chance of a better outcome. Their current work is focusing on brain cancer.